# Heart Failure Study to Evaluate Vital Signs and Overcome Low Use of Guideline-Directed Therapy by Remote Monitoring

> **NCT04292275** · NA · TERMINATED · sponsor: **Amgen** · enrollment: 18 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DEVICE:** Biobeat Wrist Watch
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT04292275
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-03-06
- **Primary completion:** 2021-10-01
- **Final completion:** 2021-10-01
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Study closed prematurely due to enrollment challenges exacerbated by COVID-19.
- **Last updated:** 2023-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04292275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04292275, "Heart Failure Study to Evaluate Vital Signs and Overcome Low Use of Guideline-Directed Therapy by Remote Monitoring". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04292275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*